The Oligonucleotide Revolution: Unveiling the Future of Science

So, like, have you heard about this cool new thing called oligonucleotide technology? It’s like totally pushing oligos to the forefront, you know? Matthew Lauber, the senior director at Waters Corporation, spilled the tea on how current technologies are making oligonucleotide development super exciting. In an exclusive chat with Pharmaceutical Technology, he was all about how these technologies are taking oligo development to the next level.

According to Lauber, synthetic oligos are super interesting because they’re like this middle ground between biologically produced drugs and small-molecule drugs. It’s like they’re bringing together the best of both worlds, you know? And guess what? The work on oligo drug development is all about modifying the oligo molecule. Even in those mRNA vaccines that gave us Nobel laureates Karikó and Weissman, the key to their success was a modified nucleotide. It’s like these modifications are unlocking a whole new world of science, our genome code, and our transcriptome code. It’s like a whole new opportunity for science, you know?

And get this, AAPS PharmSci 360 was the place to be from Oct. 22–25 in Orlando, Fl. You can check out Lauber’s video interviews about the challenges of oligonucleotide development, the need for new bioanalysis technology, and the oligonucleotide trend. It’s like the inside scoop on all things oligonucleotide!